
Triana Biomedicines
Triana Biomedicines: A biopharmaceutical pioneer, innovating disease-targeting molecular glue technology.
- 37
- Private company
- Lexington, MA, USUnited States

Triana Biomedicines: A biopharmaceutical pioneer, innovating disease-targeting molecular glue technology.
trianabio.comCrawled Oct 14, 2026
September 9, 2026 – TRIANA Biomedicines Announces Publication of Preclinical Data Supporting Clinical Advancement of TRI-611
TRIANA Biomedicines discovers and develops molecular glue therapeutics employing a target first and rational molecular glue discovery platform and focusing on degradation of high-profile cancer targets.
Triana Biomedicines, Inc. explains how it handles personal information in its website, business operations, recruitment, and clinical research, and outlines rights under applicable privacy and data protection laws.
TRIANA Biomedicines dosed the first patient in a Phase 1/2 trial testing **TRI-611**, a novel **ALK-fusion molecular glue degrader**, for treating **ALK-positive non-small cell lung cancer (NSCLC)**. The company’s **target-first and proximity-first molecular glue platform** aims to address challenging disease targets. TRI-611 represents an experimental approach to degrade ALK fusions, a driver of NSCLC progression.
Mar 2026trianabio.comNews article
Triana raises **$120 million in Series B funding** to accelerate development of its **TRI-611 molecular glue candidate**, targeting **ALK-positive non-small cell lung cancer (NSCLC)**. The investment expands the company’s oncology pipeline, focusing on novel therapeutic approaches for hard-to-treat cancers. TRI-611 represents a key asset in Triana’s strategy to deliver precision treatments for patients with limited options.
Dec 2025Life Sciences VoiceNews article
Triana secures $110 million in funding to develop molecular glues, a class of drugs designed to stabilize protein interactions for therapeutic applications. The company focuses on addressing unmet medical needs by leveraging its proprietary platform to discover and engineer these novel compounds. Molecular glues hold potential for treating diseases like cancer and autoimmune disorders by modulating protein function.
Apr 2022Chemical & Engineering NewsNews article
Triana Biomedicines secures $110 million in Series A funding to advance small-molecule therapies targeting previously undruggable cancer proteins. The company focuses on molecular glue degraders, a novel approach to disrupt disease-causing protein interactions. Development efforts aim to address unmet medical needs in oncology through innovative drug discovery.
Apr 2022BioSpaceNews article